Psychostimulant drugs for cocaine dependence
Open accessAbstract
Background Cocaine dependence is a severe disorder for which no medication has been approved. Like opioids for heroin dependence, replacement therapy with psychostimulants could be an effective therapy for treatment. Objectives To assess the effects of psychostimulants for cocaine abuse and dependence. Specific outcomes include sustained cocaine abstinence and retention in treatment. We also studied the influence of type of drug and comorbid disorders on psychostimulant efficacy. Search methods This is an update of the review previously published in 2010. For this updated review, we searched the Cochrane Drugs and Alcohol Group Trials Register, CENTRAL, MEDLINE, Embase and PsycINFO up to 15 February 2016. We handsearched references of obtained articles and consulted experts in the field. Selection criteria We included randomised parallel group controlled clinical trials comparing the efficacy of a psychostimulant drug versus placebo. Data collection and analysis We used standard methodological procedures expected by Cochrane. Main results We included 26 studies involving 2366 participants. The included studies assessed nine drugs: bupropion, dexamphetamine, lisdexamfetamine, methylphenidate, modafinil, mazindol, methamphetamine, mixed amphetamine salts and selegiline. We did not consider any study to be at low risk of bias for all domains included in the Cochrane 'Risk of bias' tool. Attrition bias was the most frequently suspected potential source of bias of the included stu…
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Topiramate has been shown to reduce alcohol use and is used off-label for alcohol use disorder.
“Topiramate has been shown to reduce alcohol use and is utilized off-label for treatment of alcohol use disorder (AUD).116”
From The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024) · cites this paper as [116]
The current body of evidence supporting prescription stimulants for treating stimulant use disorders remains inconclusive.
“the current body of evidence supporting prescription stimulants for treating stimulant use disorders remains inconclusive [58,66,67,68,69].”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [58]
Cochrane reviews have consistently highlighted the insufficiency of evidence to establish the effectiveness of certain psychotherapies for various SUDs, whether accompanied by comorbidity or not.
“Cochrane reviews have consistently highlighted the insufficiency of evidence to establish the effectiveness of certain psychotherapies for various SUDs, whether accompanied by comorbidity or not.”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [58]
High-quality research regarding the effectiveness of CBT in the treatment of stimulant use disorders is inadequate.
“An example of this shortfall is the inadequacy of high-quality research regarding the effectiveness of CBT in the treatment of stimulant use disorders [47,48,58].”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [58]
No citation lists for this paper
No citation lists for this paper yet — checked again daily.
References 128 · Cited by 110
- Authors
- Castells, X., Cunill, R., Pérez-Mañá, C., Vidal, X., & Capellà, D.
- Affiliations
- Universitat de Girona; Unit of Clinical Pharmacology, TransLab Research Group, Department of Medical Sciences; Emili Grahit, 77 Girona Catalonia Spain 17071
- Parc Sanitari Sant Joan de Déu (ES)
- Universitat Autònoma de Barcelona; Integrative Pharmacology and Systems Neuroscience Research Group, Hospital del Mar Research Institute-IMIM, Parc de Salut Mar, and Department of Pharmacology, Therapeutics and Toxicology; Doctor Aiguader 88 Barcelona Catalonia Spain 08003
- Universitat Autònoma de Barcelona (ES)
- Universitat de Girona (ES)
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2016-09-27
- Volume
- 2016
- Issue
- 9
- Pages
- CD007380-CD007380
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- PMC
- PMC6457633
- OpenAlex
- W2435538831
- Cited by
- 110
- References
- 128
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 7 · 2023: 14 · 2022: 11 · 2021: 14 · 2020: 21 · 2019: 9 · 2018: 13 · 2017: 9
- FWCI
- 1.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cochrane Database of Systematic Reviews (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- cocaine dependence, psychostimulants, cocaine abstinence, treatment retention, bupropion, d-amphetamine, lisdexamfetamine, methylphenidate, modafinil, mazindol, methamphetamine, mixed amphetamine salts, selegiline, comorbidities, cardiovascular adverse events, attrition bias, drug addiction treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review